JP2024523822A5 - - Google Patents

Info

Publication number
JP2024523822A5
JP2024523822A5 JP2023574858A JP2023574858A JP2024523822A5 JP 2024523822 A5 JP2024523822 A5 JP 2024523822A5 JP 2023574858 A JP2023574858 A JP 2023574858A JP 2023574858 A JP2023574858 A JP 2023574858A JP 2024523822 A5 JP2024523822 A5 JP 2024523822A5
Authority
JP
Japan
Application number
JP2023574858A
Other languages
Japanese (ja)
Other versions
JPWO2022256554A5 (https=
JP2024523822A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/032000 external-priority patent/WO2022256554A1/en
Publication of JP2024523822A publication Critical patent/JP2024523822A/ja
Publication of JPWO2022256554A5 publication Critical patent/JPWO2022256554A5/ja
Publication of JP2024523822A5 publication Critical patent/JP2024523822A5/ja
Pending legal-status Critical Current

Links

JP2023574858A 2021-06-02 2022-06-02 フッ素化トリプタミン化合物、その類似体、及びそれを使用する方法 Pending JP2024523822A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163195943P 2021-06-02 2021-06-02
US63/195,943 2021-06-02
US202163288313P 2021-12-10 2021-12-10
US63/288,313 2021-12-10
PCT/US2022/032000 WO2022256554A1 (en) 2021-06-02 2022-06-02 Fluorinated tryptamine compounds, analogues thereof, and methods using same

Publications (3)

Publication Number Publication Date
JP2024523822A JP2024523822A (ja) 2024-07-02
JPWO2022256554A5 JPWO2022256554A5 (https=) 2025-06-03
JP2024523822A5 true JP2024523822A5 (https=) 2025-06-03

Family

ID=84324579

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023574858A Pending JP2024523822A (ja) 2021-06-02 2022-06-02 フッ素化トリプタミン化合物、その類似体、及びそれを使用する方法

Country Status (11)

Country Link
US (1) US20240286998A1 (https=)
EP (1) EP4347559A4 (https=)
JP (1) JP2024523822A (https=)
KR (1) KR20240017363A (https=)
AU (1) AU2022287013A1 (https=)
BR (1) BR112023025340A2 (https=)
CA (1) CA3220850A1 (https=)
CO (1) CO2023018652A2 (https=)
IL (1) IL308944A (https=)
MX (1) MX2023014437A (https=)
WO (1) WO2022256554A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL326048A (en) 2021-09-03 2026-03-01 Alexander Shulgin Res Institute Inc Asymmetric allyl tryptamines
WO2023147424A1 (en) * 2022-01-27 2023-08-03 Terran Biosciences, Inc. Salts and solid forms of n-ethyl-2-(5-fluoro-1h-indol-3-yl)- n-methylethan-1-amine
US12157722B1 (en) * 2023-08-03 2024-12-03 Gilgamesh Pharmaceuticals, Inc. Crystalline hydrochloride salts of N-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine
US12129234B1 (en) 2023-08-03 2024-10-29 Gilgamesh Pharmaceuticals, Inc. Crystalline salts of N-ethyl-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine
CN121866243A (zh) * 2023-09-07 2026-04-14 耶路撒冷希伯来大学伊森姆研究发展有限公司 致幻化合物、其制备方法及其用途
WO2025104491A1 (en) * 2023-11-14 2025-05-22 Mindset Pharma Inc. Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE232201T1 (de) * 1995-06-06 2003-02-15 Schering Corp Substituierte benzokondensierte heterocyclen als neurokinin antagonisten
DE19615232A1 (de) * 1996-04-18 1997-10-23 Merck Patent Gmbh Neue Carbamoylderivate und deren Verwendung als 5-HT ¶1¶¶A¶-Antagonisten
US6100291A (en) * 1998-03-16 2000-08-08 Allelix Biopharmaceuticals Inc. Pyrrolidine-indole compounds having 5-HT6 affinity
AR021509A1 (es) * 1998-12-08 2002-07-24 Lundbeck & Co As H Derivados de benzofurano, su preparacion y uso
US6800637B2 (en) * 2002-09-12 2004-10-05 Wyeth Antidepressant indolealkyl derivatives of heterocycle-fused benzodioxan methylamines
CA3052974A1 (en) * 2017-02-09 2018-08-16 CaaMTech, LLC Compositions and methods comprising a psilocybin derivative
WO2019222552A1 (en) * 2018-05-16 2019-11-21 University Of Florida Research Foundation Methods and compositions for substituted 2,5-diketopiperazine analogs
GB201907871D0 (en) * 2019-06-03 2019-07-17 Small Pharma Ltd Therapeutic compositions
MX2022009528A (es) * 2020-02-04 2022-11-14 Mindset Pharma Inc Derivados de 3-pirrolidina-indol como agentes psicodélicos serotoninérgicos para el tratamiento de trastornos del snc.
KR20230124103A (ko) * 2020-02-18 2023-08-24 길가메쉬 파마슈티컬스, 인코포레이티드 기분 장애 치료에 사용되기 위한 특이적 트립타민
MX2023002557A (es) * 2020-09-01 2023-05-29 Enveric Biosciences Canada Inc Derivados de psilocibina halogenada y metodos de uso.
CA3192617A1 (en) * 2020-09-20 2022-03-24 Matthew BAGGOTT Advantageous tryptamine compositions for mental disorders or enhancement
CN116917305A (zh) * 2020-12-07 2023-10-20 明德赛特制药公司 用于治疗cns病症的作为血清素能剂的3-环状胺-吲哚衍生物

Similar Documents

Publication Publication Date Title
CL2025003475A1 (es) Moldeador de flujo de agua
BR102022025291A2 (https=)
BR102023014872A2 (https=)
BR102023012440A2 (https=)
BR102023010976A2 (https=)
BR102023009641A2 (https=)
BR102023008688A2 (https=)
BR102023007252A2 (https=)
BR102023005164A2 (https=)
BR102023001877A2 (https=)
BR102023000289A2 (https=)
BR102022026909A2 (https=)
BR102022023461A2 (https=)
BR202022009269U2 (https=)
BR202022005961U2 (https=)
BR202022001779U2 (https=)
BR202022000931U2 (https=)
BY13149U (https=)
BY13160U (https=)
BY13141U (https=)
BY13142U (https=)
BY13143U (https=)
BY13144U (https=)
BY13145U (https=)
BY13170U (https=)